Profile Details

Create Project

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Hire Dr. Panagiotis F.

United States

Molecular Biology Expert with 6 Years of Experience Gene Transfer

Profile Summary

I am a Molecular biologist with six years of experience on the metabolic and inflammatory mechanisms underlying the pathogenesis of atherosclerosis. My research is aiming at the development of new therapies for the treatment of Cardiovascular Disease. My studies have been focused on developing mouse models to characterized the structure/function relationship of the HDL (High Density Lipoproteins) and the risk of Cardiovascular Disease. This works has been published extensively (see publication record) and resulted on the identification of novel therapeutics for the treatment of alpha-hypolipoproteinemia and dominant type III hyperlipoproteinemia. I have also contributed in the discovery of a new role of apoA-IV in forming HDL particles. My current work is focused of the regulation of inflammatory responses in macrophages by HDL as well as the mechanism of atherosclerosis in mice lacking ABCA1 and ABCG1 transporters in macrophages. I have become proficient in gene transfer using adenoviruses, working with cell cultures and mice as well as in wide variety of molecular biology and biochemical assays employed to address scientific questions.

Subject Matter Expertise

• ☆ Adenoviruses
• ☆ Biochemistry
• ☆ Biochemical Assays
• ☆ Molecular Biology
• ☆ Lipidomics
• ☆ Pathogenesis
• ☆ Cardiovascular Disease

Services

• Consulting
• Data & AI
• Product Development

Work Experience

Post-doctoral Research Scientist

Columbia University

September 2014 - December 2016

Research Assistant

Boston University

November 2009 - July 2014

Research Assistant

University of Crete

June 2005 - April 2009

Education

PhD

University of Crete

April 2009 - July 2014

MSc

University of Crete

September 2006 - November 2008

BSc

University of Crete

September 2002 - August 2006

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

Westerterp, M., Tsuchiya, K., Tattersall, I.W., Fotakis, P., Bochem, A.E., Molusky, M.M., Ntonga, V., Abramowicz, S., Parks, J.S., Welch, C.L., et al.(2016). Deficiency of ATP-Binding Cassette Transporters A1 and G1 in Endothelial Cells Accelerates Atherosclerosis in Mice . Arteriosclerosis, Thrombosis, and Vascular Biology. 36. (7). p. 1328-1337.

Fotakis P, Kuivenhoven JA, Dafnis E, Kardassis D, Zannis VI, Biochemistry, 2015, vol. 54, no. 21, pp. 3348-3359 .

Fotakis, P., Kuivenhoven, J.A., Dafnis, E., Kardassis, D., Zannis, V.I.(2015). The effect of natural LCAT mutations on the biogenesis of HDL . Biochemistry. 54. (21). p. 3348-3359.

Zannis VI, Fotakis P, Koukos G, Kardassis D, Ehnholm C, Jauhiainen M, Chroni A, Handbook of experimental pharmacology, 2015, vol. 224, pp. 53-111 .

Tiniakou, I., Kanaki, Z., Georgopoulos, S., Chroni, A., Van Eck, M., Fotakis, P., Zannis, V.I., Kardassis, D.(2015). Natural human apoA-I mutations L141R<inf>Pisa</inf> and L159R<inf>FIN</inf> alter HDL structure and functionality and promote atherosclerosis development in mice . Atherosclerosis. 243. (1). p. 77-85.

Fotakis P, Vezeridis A, Dafnis I, Chroni A, Kardassis D, Zannis VI, Journal of lipid research, 2014, vol. 55, no. 7, pp. 1310-1323 .

Fotakis, P., Vezeridis, A., Dafnis, I., Chroni, A., Kardassis, D., Zannis, V.I.(2014). ApoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL . Journal of Lipid Research. 55. (7). p. 1310-1323.

Fotakis P, Kateifides AK, Gkolfinopoulou C, Georgiadou D, Beck M, Gründler K, Chroni A, Stratikos E, Kardassis D, Zannis VI, Journal of lipid research, 2013, vol. 54, no. 12, pp. 3281-3292 .

Fotakis P, Tiniakou I, Kateifides AK, Gkolfinopoulou C, Chroni A, Stratikos E, Zannis VI, Kardassis D, Journal of lipid research, 2013, vol. 54, no. 12, pp. 3293-3302 .

Duka A, Fotakis P, Georgiadou D, Kateifides A, Tzavlaki K, von Eckardstein L, Stratikos E, Kardassis D, Zannis VI, Journal of lipid research, 2013, vol. 54, no. 1, pp. 107-115 .

Fotakis, P., Kateifides, A.K., Gkolfinopoulou, C., Georgiadou, D., Beck, M., Gr&#252;ndler, K., Chroni, A., Fotakis, P., Kateifides, A.K., Gkolfinopoulou, C., et al.(2013). Role of the hydrophobic and charged residues in the 218-226 region of apoA-I in the biogenesis of HDL . Journal of Lipid Research. 54. (12). p. 3281-3292.

Fotakis, P., Tiniakou, I., Kateifides, A.K., Gkolfinopoulou, C., Fotakis, P., Tiniakou, I., Kateifides, A.K., Gkolfinopoulou, C., Chroni, A., Stratikos, E., et al.(2013). Significance of the hydrophobic residues 225-230 of apoA-I for the biogenesis of HDL . Journal of Lipid Research. 54. (12). p. 3293-3302.

Duka, A., Fotakis, P., Georgiadou, D., Kateifides, A., Tzavlaki, K., Von Eckardstein, L., Stratikos, E., Kardassis, D., Zannis, V.I.(2013). ApoA-IV promotes the biogenesis of apoA-IV-containing HDL particles with the participation of ABCA1 and LCAT . Journal of Lipid Research. 54. (1). p. 107-115.

BOOK

Zannis, V.I., Fotakis, P., Koukos, G., Kardassis, D., Ehnholm, C., Jauhiainen, M., Chroni, A.(2015). Hdl biogenesis, remodeling, and catabolism . Handbook of Experimental Pharmacology. 224. p. 53-111.

BOOK CHAPTER

(2012). Pleiotropic Functions of HDL Lead to Protection from Atherosclerosis and Other Diseases . Dyslipidemia - From Prevention to Treatment.